Immunocore Holdings plc

NASDAQ:IMCR

Biotechnology

Healthcare
$27.81 +0.63%

+$0.18 today

Market cap
$1.44B
Beta
0.75
P/E (TTM)
-77.5
EPS (TTM)
-$0.37
52W Low $27.56High $40.72

Volume 0.42M

Average 0.40M

IMCR Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Immunocore Holdings plcNASDAQ: IMCR

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin widens to 6.8%

Operating margin was 6.8% in Q1 FY2026, up 10.7 pp from a year earlier. On a trailing-twelve-month basis it was -7.6%, up 6.7 pp year over year. Over 3 fiscal years it widened by 18.3 pp.

Context

  • Operating margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 11 analysts of -33.9% for the fiscal year ending Dec 2026, down from -11.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
6.8%+25.7 pp QoQ
Last fiscal yearDec 2025
-11.3%+11.4 pp YoY
LTMMar 2026
-7.6%+6.7 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+10.7 pp-18.7 pp-29.4 pp
1 year+11.4 pp-22.6 pp-33.9 pp
3 years+18.3 pp-22.6 pp-40.9 pp
5 years-22.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-11.3%
Year-over-year change
+11.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How IMCR compares with its peers on the latest reported figures

  • IMCR's LTM Mar 2026 operating margin of -7.6% is the 2nd highest of the 11 companies compared; the peer median is -310.6%.
  • Its year-over-year change of +6.7 pp is the 5th highest of 11, against a peer median of -84.8 pp.
  • Over three fiscal years its change of +18.3 pp compares with a peer median of -29.5 pp.
IMCR Competitors Peer median
Operating Margin for IMCR and competitors
Company Period LTM level YoY 3-year change
CGENCompugen Ltd.LTM Mar 202642.3% +95.9 pp+514.7 pp
IMCRImmunocore Holdings plcLTM Mar 2026-7.6% +6.7 pp+18.3 pp
MGNXMacroGenics, Inc.LTM Mar 2026-40.5% +24.7 pp+32.2 pp
BNTXBioNTech SELTM Jun 2026-71.8% -41.3 pp-95.7 pp
IBRXImmunityBio, Inc.LTM Sep 2026-150.2% +165.7 pp+146148.2 pp
XNCRXencor, Inc.LTM Jun 2026-205.8% -128.2 pp-91.2 pp
RCUSArcus Biosciences, Inc.LTM Jun 2026-415.4% -286.4 pp+93.7 pp
IMTXImmatics N.V.LTM Mar 2026-570.3% -528.3 pp-394.4 pp
JANXJanux Therapeutics, Inc.LTM Mar 2026-726.3% +490.3 pp-797.6 pp
IPHAInnate Pharma S.A.FY2025-1916.9% -1508.3 pp-1817.4 pp
IMMPImmutep LimitedFY2025-2506.5% -213.2 pp+17413.5 pp
Peer median (excluding IMCR) -310.6%-84.8 pp-29.5 pp

Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue27.04M144.23M197.39M247.98M297.57M
Cost of Revenue05.29M820.63K5.54M6.21M
Gross Profit27.04M138.94M196.57M242.44M291.36M
Gross Margin100.0%96.3%99.6%97.8%97.9%
Research & Development74.31M84.31M129.42M177.44M204.47M
Selling, General & Admin82.15M0114.35M121.17M120.62M
Operating Expenses156.46M181.71M243.77M298.77M325.09M
Depreciation & Amortization5.63M4.41M3.24M3.36M2.43M
EBITDA(123.58M)(38.35M)(40.87M)(38.5M)387.18K
EBITDA Margin-457.0%-26.6%-20.7%-15.5%0.1%
Operating Income(129.42M)(42.77M)(47.2M)(56.28M)(33.74M)
Operating Margin-478.5%-29.7%-23.9%-22.7%-11.3%
Interest Income65K3.76M14.23M25.62M16.48M
Interest Expense5.57M5.41M4.08M18.84M12.17M
Other Income / Expenses(3.92M)8.95M(982.07K)14.01M19.53M
Income Before Tax(133.34M)(33.82M)(48.19M)(42.32M)(14.21M)
Pre-Tax Margin-493.0%-23.4%-24.4%-17.1%-4.8%
Income Tax Expense111.19K9.65M(4.43M)(1.48M)12.21M
Net Income(133.45M)(43.46M)(43.75M)(40.81M)(26.42M)
Net Margin-493.4%-30.1%-22.2%-16.5%-8.9%
EPS (Basic)(3.13)(0.95)(0.89)(1.02)(0.53)
EPS (Diluted)(3.00)(0.95)(0.89)(1.02)(0.53)
Weighted Avg Shares42.49M45.71M48.89M49.99M50.35M
Weighted Avg Shares (Diluted)43.86M45.71M48.89M49.99M50.35M

Immunocore Holdings plc

NASDAQ:IMCR

Intrinsic Alpha fair value

Locked

Current Price

$27.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.